Form 4: Fennec Pharmaceuticals CFO Reports Share Transaction
SEC Form 4 Filing
Robert Andrade, CFO of Fennec Pharmaceuticals, reports the acquisition and disposal of common shares on July 1, 2024.
Summary
- Robert Andrade, the Chief Financial Officer of Fennec Pharmaceuticals, filed a Form 4 with the SEC.
- The report details a transaction on July 1, 2024, involving common shares.
- Andrade acquired 1,042 shares at $0 and disposed of shares, resulting in a total of 107,397 shares beneficially owned following the reported transaction.
Sentiment
Score: 5
Explanation: This is a neutral regulatory filing, reflecting standard reporting of insider transactions. It doesn't inherently indicate positive or negative sentiment.
Industry Context
This filing is a routine disclosure related to insider trading and is required by the SEC to ensure transparency and prevent insider trading.
Stakeholder Impact
- The transaction may have a minor impact on shareholders as it reflects insider activity, but the volume is relatively small.
Key Dates
| Date | Description |
|---|---|
| 03/31/2023 | Shares awarded to Robert Andrade. |
| 07/01/2024 | Date of transaction involving common shares. |
| 07/02/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.